Anti-VEGF antibody and small-molecule drugs are already available and will most certainly need to be part of the treatment strategy for TNBC [146], although caution should be taken regarding targeting angiogenesis exclusively since at least one study suggested this may cause rebound tumor progression upon cessation of treatment [147]. Here, VEGFA is linked to neoplasm.